Massachusetts is currently home to 3202 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
NCT05265429
Recruiting
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
10/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Register for Updates
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
NCT04998396
Recruiting
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Gender:
ALL
Ages:
30 months and below
Trial Updated:
10/21/2024
Locations: Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND), Boston, Massachusetts
Conditions: Canavan Disease
Register for Updates
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
NCT02901184
Recruiting
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduc... Read More
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
10/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Intervention to Improve HIV Self-care Among People Who Inject Drugs
NCT05819411
Recruiting
This study will implement a pilot randomized controlled trial (RCT, N=70) to refine and assess the feasibility and acceptability of an emotion regulation and communication skills intervention designed to improve engagement in HIV-care among substance using HIV+ PWID sub-optimally engaged in HIV care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Fenway Community Health, Boston, Massachusetts
Conditions: Hiv, Substance Use Disorders
Register for Updates
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
NCT01356290
Recruiting
Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly... Read More
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/17/2024
Locations: Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts
Conditions: Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent
Register for Updates
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
NCT05866302
Recruiting
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the ons... Read More
Gender:
ALL
Ages:
36 months and above
Trial Updated:
10/15/2024
Locations: Dana Farber, Boston, Massachusetts
Conditions: Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Register for Updates
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
NCT05428839
Recruiting
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition to the standard airway assessment, a simple, non-invasive measurement of the width of the inside of each subjects mouth will be performed. This measurement takes 2-3 minutes to perform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Sleep Apnea, Obstructive
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04946370
Recruiting
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor pathway inhibitor (ARPI) is more effective against prostate cancer than pembrolizumab + ARPI alone.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
10/15/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Glioblastoma
Register for Updates
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
NCT04595201
Recruiting
To obtain pregnancy outcome data from patients screened for fetal genetic status using non-invasive pregnancy testing (NIPT).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Integrated Genetics, Westborough, Massachusetts
Conditions: Pregnancy
Register for Updates
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)
NCT06593951
Recruiting
The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all ages, who have a molecular diagnosis of EPM1or CSTB-null-related disease. Currently, there are no therapies that halt disease progression in any CSTB-related diseases, highlighting the urgency for translational research into this condition. The primary objective of the re... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/10/2024
Locations: Boston Childrens Hospital, Boston, Massachusetts
Conditions: Progressive Myoclonus Epilepsy Type 1, EPM1, CSTB-related Disease, Myoclonus Epilepsies, Progressive, Unverricht-Lundborg Disease, Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, PME, Progressive Myoclonus-Epilepsies
Register for Updates